Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced that the phase III clinical trial evaluating Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints. The full study results will be presented this year during a medical congress.
Based on these results, Ipsen intends to apply for the addition of the subcutaneous route, alongside the intramuscular route, to the label of triptorelin pamoate 11.25 mg.
Claude Bertrand, Executive Vice-President, Research & Development and Chief Scientific Officer of Ipsen stated: "The efficacy and safety of triptorelin pamoate 11.25 mg in the treatment of patients with prostate cancer is well-established. The availability of an efficacious and safe subcutaneous formulation offers a more convenient and suitable way of administrating triptorelin pamoate to patients on oral anticoagulants or cachectic patients for whom intramuscular administration is not recommended. Through its willingness to offer a wider and more adapted product range, Ipsen reaffirms its positioning as a patient-centric organization".
How different types of bread impact cancer risk